Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial
Stem Cell Research & Therapy volume 14, Article number: 78 (2023)
Posterolateral spinal fusion is the standard surgical approach for patients with degenerative disc disease. In our previously published article, we reported a 5-years follow-up of a phase I/II clinical trial in patients undergoing spinal fusion with autologous mesenchymal stem cells (MSCs) embedded in tricalcium phosphate. In the current manuscript, we have updated the results with a 10-year follow-up, the longest reported to date in this setting. After clinical and radiological evaluation, safety of the procedure was further confirmed in all 11 treated patients, with no evidence of tumor, infection, inflammatory reaction, or heterotopic ossification related to the administration of MSCs. Regarding clinical efficacy, low back pain and radicular pain (both assessed by the visual analogue scale—VAS), and the Owestry Disability Index remained significantly lower compared to pre-intervention. Radiologic evaluation demonstrated spinal fusion in all cases, improving over time. Finally, quality of life improved significantly also during follow-up. In summary, the use of tricalcium phosphate-embedded autologous MSCs with lumbar posterolateral arthrodesis is safe and potentially provides long-term benefits for 10 years.
To the editor,
The gold-standard surgical approach to treat lumbar degenerative disc disease (DDD) is posterolateral spinal fusion . Generally, the procedure is complemented by the addition of autologous or allogeneic bone grafts or bone substitutes. Although high fusion rates can be obtained with autologous bone graft, the procedure has some disadvantages, such as pain and increased surgical time .
The use of mesenchymal stem cells (MSCs) in spinal fusion procedures has raised as a potentially attractive approach, based on the ability of these cells to differentiate into osteoblast together with their strong anti-inflammatory and immunomodulatory capacity . Although benefit has been suggested in animal models , information on its clinical application is scarce.
In a previous work , we presented the results of a phase I/II clinical trial of MSCs with tricalcium phosphate combined with spinal fusion for DDD. In that initial report, we provided the 5-year follow-up for the 11 patients treated. In the current manuscript, we provide the outcome after 10-years.
For the 10-year follow-up analysis, the 11 patients previously reported were assessed in person both clinically and radiologically. As in the previous study, pain was evaluated by means the visual analog scale (VAS), functional status by means of the Oswestry score and physical functioning, assessing this subsection of 10 items from the SF36 questionnaire. Lumbar spine X-ray was also performed. Updated data on comorbidities and complications were also collected.
Statistical analyses were performed in R 4.2.0. All numerical variables followed a normal distribution (Shapiro–Wilk test). For the comparative analysis of quantitative variables, the Student’s t-test for paired samples was used comparing pre-intervention versus 10 years, pre-intervention versus 1 year, and 1 year versus 10 years. In addition, an Anova test for paired samples was performed to compare the three experimental groups.
The most important finding of the long-term evaluation after 10 years is the fact that no late adverse events were observed in this period after in-person clinical and radiological evaluation of the treated patients. These includes local tumoral transformation, local infections, or lumbar heterotopic ossification related to the administration of MSCs. Solid radiological fusion was present at this late timepoint in 100% of the patients, without instrumentation loosening, segmental instabilities, lytic areas or pseudoarthrosis. The updated 10-years analyses showed a maintained significant decrease (p = 0.026) of low back pain intensity compared to the pre-surgery assessment (Fig. 1A). The VAS scale for radicular pain (Fig. 1B) was also significantly lower at this late timepoint (p = 0.046). Regarding disability evaluation, the Owestry index (Fig. 1C) was significantly decreased 10 years after surgery (p = 0.015). Finally, 10-years physical functioning evaluation from the SF-36 questionnaire (Fig. 1D), was also significantly improved compared to that of the pre-surgical status (p = 0.026).
In summary, our 10-year evaluation results show that the use of autologous MSCs embedded in a tricalcium phosphate scaffold in addition to posterolateral arthrodesis is a safe procedure and suggest potential benefits at the clinical, radiological, and physical functioning levels, that should be demonstrated in larger phase II or III randomized trials.
Availability of data and materials
The datasets generated and analyzed during the current study are included in this published article. Additional data analyzed during this study are available from the corresponding author on reasonable request.
Mesenchymal stem cells
Visual analog scale
Degenerative disc disease
Reid PC, Morr S, Kaiser MG. State of the union: a review of lumbar fusion indications and techniques for degenerative spine disease. J Neurosurg Spine. 2019;31:1–14. https://doi.org/10.3171/2019.4.SPINE18915.
Sheha ED, Meredith DS, Shifflett GD, Bjerke BT, Iyer S, Shue J, et al. Postoperative pain following posterior iliac crest bone graft harvesting in spine surgery: a prospective, randomized trial. Spine J. 2018;18:986–92. https://doi.org/10.1016/j.spinee.2017.10.011.
Oryan A, Kamali A, Moshiri A, Baghaban EM. Role of mesenchymal stem cells in bone regenerative medicine: What is the evidence? Cells Tissues Organs. 2017;204:59–83. https://doi.org/10.1159/000469704.
Salamanna F, Sartori M, Brodano GB, Griffoni C, Martini L, Boriani S, et al. Mesenchymal stem cells for the treatment of spinal arthrodesis: from preclinical research to clinical scenario. Stem Cells Int. 2017;2017:3537094. https://doi.org/10.1155/2017/3537094.
Blanco JF, Villarón EM, Pescador D, da Casa C, Gómez V, Redondo AM, et al. Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up. Stem Cell Res Ther. 2019;10:63. https://doi.org/10.1186/s13287-019-1166-4.
This clinical trial was supported by Grant Code TRA-138 from Ministerio de Sanidad (Spain). Any additional role in the study was performed by the funding body.
Ethics approval and consent to participate
This clinical trial protocol was reviewed and approved by the Ethics Committee of the University Hospital of Salamanca (Approval number: 10820) and the Spanish Medicine Agency (AEMPS). This project, entitled: “Treatment of lumbar intervertebral degenerative discopathy using instrumented post-lateral arthrodesis and autologous mesenchymal stem cells,” was approved on February 22, 2010. Furthermore, all patients signed the approved informed consent and all the procedures where in accordance with the principles of the Declaration of Helsinki. Trial registration: no. EudraCT: 2010-018335-17; code Identifier: NCT01513694 (clinicaltrials.gov).
Consent for publication
All patients signed de informed consent, including consent for publication. No personal details or contact data of patient was included.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gomez-Ruiz, V., Blanco, J.F., Villarón, E.M. et al. Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial. Stem Cell Res Ther 14, 78 (2023). https://doi.org/10.1186/s13287-023-03298-4